Effective Treatments Identified for Pediatric Complication of COVID
PHOENIX — First-line treatment with methylprednisolone and second-line treatment with tocilizumab (Actemra) shortened hospital stays for children with pediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 (PIMS-TS; also referred to as multisystem inflammatory syndrome in children [MIS-C]), according to results of a two-stage clinical trial from the RECOVERY collaborative group. In 214 children randomly assigned […]
FDA Authorizes IL-6 Inhibitor for Severe COVID-19 Patients
Tocilizumab (Actemra), an interleukin-6 (IL-6) inhibitor, was authorized to treat certain hospitalized COVID-19 patients, the FDA announced late on Thursday. The drug received emergency use authorization (EUA) for hospitalized patients ages 2 and up who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). It is […]